SCHEDULE 13G/A: AIGH Capital Management and Orin Hirschman Disclose 9.9% Stake in Aprea Therapeutics

Investment firm AIGH Capital Management LLC and its managing member Orin Hirschman have reported a 9.9% beneficial ownership in Aprea Therapeutics, Inc. as of December 31, 2024.

Summary

• Orin Hirschman, AIGH Capital Management LLC, and AIGH Investment Partners LLC (collectively, the "Reporting Persons") have jointly filed a Schedule 13G.
• The Reporting Persons beneficially own an aggregate of 539,300 shares of Aprea Therapeutics, Inc. Common Stock.
• This ownership represents 9.9% of the outstanding class of Aprea Therapeutics' Common Stock.
• The Reporting Persons hold sole voting power and sole dispositive power over all 539,300 shares.
• An additional 372,412 common shares issuable upon the exercise of warrants are excluded from the reported beneficial ownership due to beneficial ownership limitations on exercise.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive. While a Schedule 13G is a factual disclosure of ownership, the emergence of a significant stake by an investment firm is generally viewed as a positive signal of confidence in the company's prospects, even if the filing itself is passive.

Positives

• The disclosure of a significant beneficial ownership stake by an investment firm like AIGH Capital Management can be interpreted by the market as a vote of confidence in Aprea Therapeutics, Inc.

Negatives

• The beneficial ownership limitation on the exercise of warrants means that the Reporting Persons cannot currently convert an additional 372,412 common shares, which could limit their potential upside from these warrants.

Risks

• The Reporting Persons are subject to beneficial ownership limitations on the exercise of warrants, preventing them from immediately acquiring an additional 372,412 common shares.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Aprea Therapeutics' future performance or strategic direction.

Industry Context

This Schedule 13G filing indicates a significant passive investment by AIGH Capital Management in Aprea Therapeutics, a company operating in the therapeutics/biotechnology sector. Such disclosures are common in the investment landscape, reflecting an investor's belief in the long-term value of a company within its industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an institutional investor may influence market perception and potentially the share price of Aprea Therapeutics, Inc.

Key Dates

Keywords

Aprea Therapeutics, AIGH Capital Management, Orin Hirschman, Schedule 13G, beneficial ownership, common stock, investment, biotechnology, pharmaceuticals